Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab, biosimilar) in Finland

 Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab, biosimilar) in Finland

Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab, biosimilar) in Finland

Shots:

  • Amgevita is indicated to treat chronic inflammatory diseases such as moderate-to-severe RA, IBD and psoriasis
  • Amgen Biosimilar Amgevita, is a novel adalimumab’s biosimilar to be marketed in Finland. On 23 Mar, 2017 Amgevita received EU approval for inflammatory diseases in adults
  • In 2013, Orion marketed first infliximab’s biosimilar in Finland post its marketing approval. Amgevita is the third biosimilar marketed by Orion, and novel drug injected at home

Click here to read full press release/ article | Ref: Orion | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post